Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan RI Compounded Drugs Prior…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Compounded Drug Products

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization documentation requirements, clinical coverage criteria, continuation criteria, exclusions, and maximum coverage duration for compounded drug products under Neighborhood Health Plan of Rhode Island.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyCompounded Drug Products
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit a PA request listing each active ingredient with dosage form, strengths, quantities, and manufacturer NDC OR ensure the dispensing pharmacy claim includes all active and inactive ingredients with dosage form, strengths, quantities, and manufacturer NDC; missing documentation may lead to dismissal.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes.

    1Minimum legend drug requirement
    12Maximum coverage duration (months)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Summary

    Compounded drug products are covered with prior authorization when the policy criteria are met. Coverage requires submission of the documentation listed in Section I and fulfillment of the approval criteria in Section II. Coverage stance: covered_with_criteria. Status: CURRENT.

    Key policy facts
    Coverage stancecovered_with_criteria
    ScopeDefines prior authorization documentation requirements, clinical coverage criteria, continuation criteria, exclusions, and maximum coverage duration for compounded drug products under Neighborhood Health Plan of Rhode Island.
    Minimum legend drug requirement1 legend drug required in the compounded product
    Maximum coverage durationUp to 12 months as determined by FDA dosing guidance and internal policies

    Medical-Necessity Criteria

    Criteria for approval (Initial prior authorization)

    Compounded drug products will be covered with prior authorization when the following criteria are met:

    ALL of the following

    • The compounded product contains at least one legend drug.
    • Each of the active ingredients in the compound are FDA-approved for the indication for which the compound is being prescribed OR are for a medically accepted indication as defined in one of the following: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or peer-reviewed published medical literature indicating sufficient evidence exists to support use.
    • Each active ingredient in the compound are FDA-approved drugs or compendia supported AND the compound route of administration is the same as the FDA-approved route of administration for each active ingredient, if applicable.
    • The dosage or concentration of each active ingredient in the compound is equal to or below the FDA-approved dosage or concentration AND the prescribed dose of the compounded product falls within the FDA-approved labeling or within compendia supported dosing guidelines.

    Exclusion Criteria

    Exclusion criteria

    The requested compounded medication contains an ingredient considered not medically necessary in a compound.
    The requested compounded medication contains any ingredients that are not covered per the Neighborhood Health Plan of Rhode Island Pharmacy Benefit Exclusion policy or are being used for any non-covered indication per that policy (e.g. drugs used for cosmetic purposes).
    For Neighborhood Medicaid benefit requests only: The requested compounded medication (both active and inactive ingredients) contains drugs or products whose manufacturer does not participate in the Medicaid Drug Rebate Program (MDRP).
    Denial Risk

    Exclusion-based denial risk

    Claims will be denied if the compounded product contains ingredients that trigger exclusions. Triggers include: ingredients considered not medically necessary, ingredients listed on the plan's Pharmacy Benefit Exclusion policy or used for non-covered indications (e.g., cosmetic uses), and — for Neighborhood Medicaid requests only — any active or inactive ingredients whose manufacturer does not participate in the Medicaid Drug Rebate Program (MDRP).

    Coding and Documentation Codes

    Referenced code types required in documentationNDC
    No codes listed
    Billing Rule

    Claims documentation requirement

    Dispensing pharmacy claims must include all active and inactive ingredients used in the compound with dosage form, strengths, quantities, and manufacturer National Drug Code (NDC). This information can be submitted on the dispensing claim instead of on the PA request to satisfy documentation requirements.

    Provider Actions & Prior Authorization

    Prior Authorization

    Prior authorization documentation required

    Submit a prior authorization request that lists each active ingredient in the compound including dosage form, strengths, quantities, and manufacturer NDC. Alternatively, ensure the dispensing pharmacy claim includes all active and inactive ingredients with dosage form, strengths, quantities, and manufacturer NDC. Missing this documentation may result in dismissal of the request as invalid.

    Documentation Required

    Provide clinical supporting documentation

    Provide all relevant clinical documentation to support medical necessity and alignment with FDA labeling or recognized compendia for each active ingredient.

    • Laboratory values
    • Treatment plan
    • Medical chart notes

    Background & Definitions

    This policy governs coverage of compounded drug products requiring prior authorization and specifies that each active ingredient must be an FDA-approved drug or supported by recognized compendia (AHFS‑DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi‑Drugs, or peer‑reviewed literature). It requires the compound to contain at least one legend drug, that the route of administration and dosages/concentrations align with FDA‑approved routes and dosing or compendia‑supported dosing, and that all relevant clinical documentation is provided. Up to 12 months of coverage may be authorized per FDA dosing guidance and internal policies, and compounds containing excluded or non‑covered ingredients (or, for Medicaid, products from manufacturers not participating in MDRP) will be denied.

    TermDefinition
    Legend drugA drug that is required by federal or state law to be dispensed only with a prescription.
    CompendiaStandard reference compendia listed: AHFS-DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs.
    MDRPMedicaid Drug Rebate Program.

    Revision History

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyCompounded Drug Products
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit a PA request listing each active ingredient with dosage form, strengths, quantities, and manufacturer NDC OR ensure the dispensing pharmacy claim includes all active and inactive ingredients with dosage form, strengths, quantities, and manufacturer NDC; missing documentation may lead to dismissal.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaExclusion CriteriaCoding and Documentation CodesProvider Actions & Prior AuthorizationBackground & DefinitionsRevision History
  1. All relevant documentation (e.g. lab values, treatment plan, medical chart notes) is provided.
  2. One of the following must be met

    • There is a current supply shortage of the commercially manufactured product OR the commercial product has been discontinued by the pharmaceutical manufacturer for reasons other than lack of safety or efficacy.
    • The member has a medical need for a dosage form or dosage strength that is not available commercially or manufactured.
    • The member has experienced an inadequate treatment response or intolerance (e.g., allergen or adverse effects due to inactive ingredients) to all commercially available formulary first line agents, including the generic and biosimilar alternative, if available.
  3. Operational note

    Continuation of therapy (Renewal criteria)

    ALL of the following

    • Member meets all initial criteria in sections I & II.
    • Member is tolerating treatment and is not experiencing any unacceptable toxicity from the drug.
    • Member has disease stabilization or improvement in disease (as defined by established clinical practice guidelines).
    ref
    title":"Continuation of therapy (Renewal criteria)"},{

    Documentation required to initiate prior authorization

    Submission of the following information is necessary to initiate the prior authorization review:

    Provide either

    • Each active ingredient used in the compound are included on the prior authorization request (e.g. dosage form, strengths, quantities, manufacturer National Drug Code (NDC)).
    • The dispensing pharmacy claim has been submitted with all active and inactive ingredients used in the compound (e.g. dosage form, strengths, quantities, manufacturer National Drug Code (NDC)).
    Operational note: Any compounded drug request missing the above documentation may be dismissed as invalid.
    • Non‑medically necessary ingredients in the compound
    • Ingredients excluded by the Neighborhood Health Plan of Rhode Island Pharmacy Benefit Exclusion policy (including non‑covered indications such as cosmetic use)
    • For Medicaid only: any ingredient (active or inactive) from a manufacturer not participating in MDRP

    For continuation (renewal), providers must document that the member meets initial criteria, is tolerating treatment without unacceptable toxicity, and has disease stabilization or improvement. Provide supporting clinical documentation (e.g., lab values, treatment plan, medical chart notes) and reference compendia or FDA alignment for each active ingredient when submitting renewal requests.